OncoGenex Pharmaceuticals Inc (OGXI)

0.35
NASDAQ : Health Care
Prev Close 0.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.33 / 1.32
Avg Volume 156.30K
Exchange NASDAQ
Shares Outstanding 30.09M
Market Cap 10.83M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement

OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement

Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

8 Breakout Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering major breakout trades.

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis

Data Safety Monitoring Board Recommends Continuation of Trial as Planned in Bladder Cancer Patients

OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment

OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment

Topline Results in Poor Prognosis Subpopulation Expected by End of Year

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes

Data Presented at 2015 European Cancer Congress Includes Further Analysis from Borealis-1TM Trial of Apatorsen in Metastatic Bladder Cancer

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a strong on high relative volume candidate